丁酸钠下调IRAK1改善肠易激综合征内脏高敏感

doi:10.6040/j.issn.1671-7554.0.2018.186

摘要/Abstract

摘要： 目的探究丁酸钠改善肠易激综合征(IBS)内脏高敏感性机制。方法纳入27例腹泻型肠易激综合征(IBS-D)患者及22例对照共49例参与者,免疫组化检测肠上皮IRAK1蛋白表达量,Spearman秩和检验分析IRAK1蛋白表达与腹痛程度和频率评分相关性。2,4,6-三硝基苯磺酸灌肠建立IBS疾病动物模型,丁酸钠灌肠干预,结肠扩张实验观察内脏敏感性变化,ELISA检测结肠IRAK1蛋白表达水平,Spearman秩和检验分析动物结肠IRAK1表达与内脏疼痛阈值相关性。以IL-33、丁酸钠干预HT-29细胞,Western blotting观察IRAK1蛋白表达变化。结果 IBS-D患者结肠上皮IRAK1蛋白表达高于对照组,结肠上皮IRAK1表达水平与腹痛程度评分呈正相关(r=0.676, P<0.001),与腹痛频率评分呈正相关(r=0.725, P<0.001)。丁酸钠干预可降低IBS动物结肠IRAK1蛋白表达、提高内脏疼痛阈值,动物结肠IRAK1蛋白表达与内脏疼痛阈值呈负相关(r=-0.655,P<0.001)。IL-33可使细胞IRAK1蛋白表达上调,丁酸钠预处理可减弱此效应。结论丁酸钠可能通过下调IRAK1蛋白表达水平改善IBS内脏高敏感性。

关键词: 丁酸钠, 白介素-1受体相关激酶1, 肠易激综合征, 内脏高敏感

Abstract: Objective To investigate the role and mechanism of sodium butyrate in the treatment of irritable bowel syndrome(IBS). Methods A total of 49 participants comprised of 27 diarrhea-dominant IBS(IBS-D)patients and 22 controls were included. The protein expression of interleukin-1 receptor-associated kinase 1(IRAK1)in the colonic epithelium was detected with immunohistochemistry staining. The relationship between the IRAK1 protein expression and abdominal pain scores was analyzed with Spearman correlation analysis. After the animal models of IBS were established by 2,4,6-trinitrobenzene sulphonic acid enema, they were treated with sodium butyrate enema. The visceral hypersensitivity was observed using colorectal distension. The IRAK1 expression was determined with enzyme linked immunosorbent assay(ELISA). The relationship between IRAK1 expression and visceral pain threshold was analyzed with Spearman correlation analysis. After the HT-29 cell lines were treated with IL-33 and sodium butyrate, the IRAK1 protein expression was detected with Western blotting. Results Patients with IBS-D showed a higher expression of IRAK1 in colonic epithelium than the controls and IRAK1 expression was positively correlated with abdominal pain severity scores(r=0.676, P<0.001)and frequency scores(r=0.725, P<0.001). IBS animal models treated with sodium butyrate enema exhibited a lower expression of IRAK1 in the colon tissues and a higher visceral pain threshold. The IRAK1 protein expression was negatively correlated with pain threshold(r=-0.655, P<0.001). IL-33 stimulation could upregulate the protein expression of IRAK1 in HT-29 cell lines, while sodium butyrate pretreatment could diminish the effect. Conclusion Sodium butyrate may ameliorate visceral hypersensitivity in irritable bowel syndrome by down-regulating the protein expression of IRAK1.

Key words: Sodium butyrate, Interleukin-1 receptor-associated kinase 1, Irritable bowel syndrome, Visceral hypersensitivity

中图分类号:

R574

李竹青,张文雪,李理想,王鹏,于岩波,左秀丽,李延青. 丁酸钠下调IRAK1改善肠易激综合征内脏高敏感[J]. 山东大学学报 (医学版), 2018, 56(9): 23-28.

LI Zhuqing, ZHANG Wenxue, LI Lixiang, WANG Peng, YU Yanbo, ZUO Xiuli, LI Yanqing. Sodium butyrate ameliorates visceral hypersensitivity by down-regulating IRAK1 in irritable bowel syndrome[J]. Journal of Shandong University (Health Sciences), 2018, 56(9): 23-28.

参考文献

[1] Lehmann D, Radomski N, Lutke-Eversloh T. New insights into the butyric acid metabolism of Clostridium acetobutylicum[J]. Appl Microbiol Biotechnol, 2012, 96(5):1325-1339.
[2] Vital M, Howe AC, Tiedje JM. Revealing the bacterial butyrate synthesis pathways by analyzing(meta)genomic data[J]. MBio, 2014, 5(2):e889. doi:10.1128/mBio.00889-14.
[3] Kumari R, Ahuja V, Paul J. Fluctuations in butyrate-producing bacteria in ulcerative colitis patients of North India[J]. World J Gastroenterol, 2013, 19(22):3404-3414.
[4] Van den Abbeele P, Belzer C, Goossens M, et al. Butyrate-producing clostridium cluster XIVa species specifically colonize mucins in an in vitro gut model[J]. ISME, 2013, 7(5):949-961.
[5] Mishiro T, Kusunoki R, Otani A, et al. Butyric acid attenuates intestinal inflammation in murine DSS-induced colitis model via milk fat globule-EGF factor 8[J]. Lab Invest, 2013, 93(7):834-843.
[6] Pozuelo M, Panda S, Santiago A, et al. Reduction of butyrate- and methane-producing microorganisms in patients with irritable bowel syndrome[J]. Sci Rep, 2015, 5:12693. doi:10.1038/srep12693.
[7] Jain A, Kaczanowska S, Davila E. IL-1 receptor-associated kinase signaling and its role in inflammation, cancer progression, and therapy resistance[J]. Front Immunol, 2014, 5:553. doi:10.3389/fimmu.2014.00553.
[8] Heiseke AF, Jeuk BH, Markota A, et al. IRAK1 drives intestinal inflammation by promoting the generation of effector the cells with optimal gut-homing capacity[J].J Immunol, 2015, 195(12):5787-5794.
[9] Jin Z, Liang F, Yang J, et al. hnRNP I regulates neonatal immune adaptation and prevents colitis and colorectal cancer[J]. PLoS Genet, 2017,13(3):e1006672. doi:10.1371/journal.pgen.1006672.
[10] Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders[J]. Gastroenterology, 2006, 130(5):1480-1491.
[11] Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome[J]. Gastroenterology, 2004, 126(3):693-702.
[12] Liu Y, Xu Y, Ma H, et al. Hepatitis B virus X protein amplifies TGF-beta promotion on HCC motility through down-regulating PPM1a[J]. Oncotarget, 2016, 7(22):33125-33135.
[13] Qi QQ, Chen FX, Zhao DY, et al. Colonic mucosal N-methyl-D-aspartate receptor mediated visceral hypersensitivity in a mouse model of irritable bowel syndrome[J]. J Dig Dis, 2016, 17(7):448-457.
[14] Zhou Q, Yang L, Larson S, et al. Decreased miR-199 augments visceral pain in patients with IBS through translational upregulation of TRPV1[J]. GUT, 2016, 65(5):797-805.
[15] Defrees DN, Bailey J. Irritable bowel syndrome: epidemiology, pathophysiology, diagnosis, and treatment[J]. Prim Care, 2017, 44(4):655-671.
[16] Hungin AP, Paxman L, Koenig K, et al. Prevalence, symptom patterns and management of episodic diarrhea in the community:a population-based survey in 11 countries[J]. Aliment Pharmacol Ther, 2016, 43(5):586-595.
[17] Simren M, Barbara G, Flint HJ, et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report[J]. GUT, 2013, 62(1): 159-176.
[18] Moraru IG, Moraru AG, Dumitrascu DL. Irritable bowel syndrome and the small intestinal microflora. What do we know?[J]. Rom J Intern Med, 2015, 53(1):103-107.
[19] Camilleri M, Madsen K, Spiller R, et al. Intestinal barrier function in health and gastrointestinal disease[J]. Neurogastroenterol Motil, 2012, 24(6):503-512.
[20] Sinagra E, Pompei G, Tomasello G, et al. Inflammation in irritable bowel syndrome: Myth or new treatment target?[J]. World J Gastroenterol, 2016, 22(7):2242-2255.
[21] Brown K, Abbott DW, Uwiera RRE, et al. Removal of the cecum affects intestinal fermentation, enteric bacterial community structure, and acute colitis in mice[J]. Gut Microbes, 2018, 9(3):218-235.
[22] Zheng L, Kelly CJ, Battista KD, et al. Microbial-derived butyrate promotes epithelial barrier function through IL-10 receptor-dependent repression of claudin-2[J]. J Immunol, 2017, 199(8):2976-2984.
[23] Zaleski A, Banaszkiewicz A, Walkowiak J. Butyric acid in irritable bowel syndrome[J]. Prz Gastroenterol, 2013, 8(6):350-353.
[24] Elce A, Amato F, Zarrilli F, et al. Butyrate modulating effects on pro-inflammatory pathways in human intestinal epithelial cells[J]. Benef Microbes, 2017, 8(5):841-847.
[25] Vollmer S, Strickson S, Zhang T, et al. The mechanism of activation of IRAK1 and IRAK4 by interleukin-1 and Toll-like receptor agonists[J]. Biochem J, 2017, 474(12):2027-2038.
[26] Zhao Q, Chen G. Role of IL-33 and its receptor in T cell-mediated autoimmune diseases[J]. Biomed Res Int, 2014, 2014:587376. doi:10.1155/2014/587376.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed